Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study

Duvelisib (IPI‐145) is an oral dual inhibitor of phosphoinositide‐3‐kinase (PI3K)‐δ and ‐γ in clinical development for the treatment of hematologic malignancies, including indolent non‐Hodgkin lymphoma (iNHL). In a Phase 1, open‐label study to determine the maximum tolerated dose (MTD), pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Flinn, Ian W., Patel, Manish, Oki, Yasuhiro, Horwitz, Steven, Foss, Francine F., Allen, Kerstin, Douglas, Mark, Stern, Howard, Sweeney, Jennifer, Kharidia, Jahnavi, Kelly, Patrick, Kelly, Virginia M., Kahl, Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220789/
https://www.ncbi.nlm.nih.gov/pubmed/30033575
http://dx.doi.org/10.1002/ajh.25228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220789/
https://www.ncbi.nlm.nih.gov/pubmed/30033575
http://dx.doi.org/10.1002/ajh.25228

Ejemplares similares